1-20 of 140
pembrolizumab
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma

Free
Clinical Trials & Observations
Pamela B. Allen, Hatice Savas, Andrew M. Evens, Ranjana H. Advani, Brett Palmer, Barbara Pro, Reem Karmali, Eric Mou, Jeffrey Bearden, Gary Dillehay, Robert A. Bayer, Robert M. Eisner, Joan S. Chmiel, Kaitlyn O’Shea, Leo I. Gordon, Jane N. Winter
Journal: Blood
Blood (2021) 137 (10): 1318–1326.
https://doi.org/10.1182/blood.2020007400
Published: 2021
Includes: Supplemental data
Journal Articles

A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma

Free
Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Edus H. Warren, MD PhD, David M. Kurtz, MD PhD, Hilary Coye, PA-C, Jacquelin Vandermeer, BS, Hongyan Du, MD, Adam Greenbaum, MD PhD, Ajay K. Gopal, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5299.
https://doi.org/10.1182/blood-2019-124997
Published: 2019
Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Free
Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5483.
https://doi.org/10.1182/blood-2019-132211
Published: 2019
Journal Articles

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Free
Eliza A Hawkes, Kate Manos, Geoff Chong, Jodie Palmer, Michael MacManus, Colm Keane, MD, Andrew Scott, Jake Shortt, MBBS FRACP FRCPA PhD, David Ritchie, MD PhD, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze-Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor
Journal: Blood
Blood (2019) 134 (Supplement_1): 5328.
https://doi.org/10.1182/blood-2019-122635
Published: 2019
Journal Articles

Three Drug Regimens for Newly Diagnosed Multiple Myeloma Transplant-Ineligible Elderly Patients - a Systematic Review

Free
Abdul Aziz Siddiqui, MD, Kazi Najamus-saqib Khan, Arafat Ali Farooqui, MD, Muhammad Saad Farooqi, MD, Muhammad Junaid Tariq, MD, Faiz Anwer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5574.
https://doi.org/10.1182/blood-2019-132095
Published: 2019
Journal Articles

The IRE1-XBP1s Pathway Impairment Underpins NK Cell Dysfunction in Hodgkin Lymphoma, That Is Partly Restored By PD-1 Blockade

Free
Karolina Bednarska, Jay Gunawardana, PhD, Frank Vari, PhD, Qingyan Cui, PhD, Gayathri Thillaiyampalam, MSc, BSc, Samantha Stehbens, PhD, Sally Mujaj, PhD, Jamie Nourse, PhD, Alexandre Cristino, PhD, Maher K. Gandhi, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2795.
https://doi.org/10.1182/blood-2019-126372
Published: 2019
Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Free
Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3050.
https://doi.org/10.1182/blood-2019-125411
Published: 2019
Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Free
Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3880.
https://doi.org/10.1182/blood-2019-131061
Published: 2019
Journal Articles

Utilization of Immune Checkpoint Inhibitors for Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) in Oncology Community Practices

Free
Ajeet Gajra, MD FACP, Andrew J Klink, PhD MPH, Chadi Nabhan, MDMBA, FACP, Bruce Feinberg, DO
Journal: Blood
Blood (2019) 134 (Supplement_1): 4057.
https://doi.org/10.1182/blood-2019-129632
Published: 2019
Journal Articles

Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment

Free
Locke J. Bryan, MD, Scott E. Smith, MD PhD, Pamela Allen, MDMSc, Carla Casulo, Brett Alan Palmer, BS, Reem Karmali, MD, Barbara Pro, MD, Denise M Scholtens, PhD, Hatice Savas, MD, Jayesh Mehta, MD, Leo I. Gordon, MD, Jane N. Winter, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4029.
https://doi.org/10.1182/blood-2019-123879
Published: 2019
Journal Articles

Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study

Free
N. Nora Bennani, MD, Grzegorz Nowakowski, MD, Lisa M. Rimsza, MD, Alex A Adjei, MD PhD, Laurence Doyle, Stephen M Ansell, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4090.
https://doi.org/10.1182/blood-2019-129104
Published: 2019
Journal Articles

Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas

Free
Stefan K. Barta, MD MRCP, MS, Nathan H. Fowler, MD, Jasmine Zain, MD, Jia Ruan, MD PhD, Sonali M. Smith, MD, Stephen J. Schuster, MD, Sunita D Nasta, MD, Jakub Svoboda, MD, James N Gerson, MD, Daniel J. Landsburg, MD, Elise A. Chong, MD, Henry C. Fung, FRCP,MBBChir, Kerry S Campbell, PhD, Nadia Khan, MD, Richard I. Fisher, MD, Carlyn Rose Tan, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4031.
https://doi.org/10.1182/blood-2019-125385
Published: 2019
Journal Articles

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Free
Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Donald Jackson, PhD, Michael Robbins, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Samir Parekh, MD, Jonathan J Keats, PhD, Daniel Auclair
Journal: Blood
Blood (2019) 134 (Supplement_1): 3093.
https://doi.org/10.1182/blood-2019-131274
Published: 2019
Journal Articles

High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

Free
Alison J. Moskowitz, MD, Gunjan L. Shah, MDMS, Heiko Schoder, MD, Helen Hancock, ANP, Theresa Davey, MMSc, PA-C, Christopher Joong, BS, Lauren Pomerantz, BS, Christine Jarjies, MS, Anita Kumar, MD, Oscar B Lahoud, MD, Connie Lee Batlevi, MD PhD, Paul A. Hamlin, MD, David J. Straus, MD, Ildefonso Rodriguez-Rivera, MD, Colette Owens, MD, Philip Caron, MD PhD, Donald Steven Colbourn, MD, Andrew M. Intlekofer, MD PhD, Audrey Hamilton, MD, Steven M. Horwitz, MD, Erel Joffe, MDMSc, M. Lia Palomba, MD, Ariela Noy, MD, Matthew J Matasar, MD, Santosha Vardhana, MD PhD, Gottfried R. von Keudell, MD PhD, Joachim Yahalom, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Craig H. Moskowitz
Journal: Blood
Blood (2019) 134 (Supplement_1): 2837.
https://doi.org/10.1182/blood-2019-127575
Published: 2019
Journal Articles

Open-Label Pilot Study of Genetically Engineered NY-ESO-1 Specific T Cells (GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma

Free
Taiga Nishihori, MD, Jonathan L. Kaufman, MD, James E. Hoffman, Kristin Blouch, Sunil Pandit, Emily Butler, Amit Jain, Yuehui Wu, M. Phillip DeYoung, Aisha N. Hasan, Aaron P. Rapoport
Journal: Blood
Blood (2019) 134 (Supplement_1): 3134.
https://doi.org/10.1182/blood-2019-128059
Published: 2019
Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Free
Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 3236.
https://doi.org/10.1182/blood-2019-125963
Published: 2019
Journal Articles

Improving End of Life Care for Hematology-Oncology Patients within the Rossy Cancer Network

Free
Victoria Korsos, BSc, Allaa Ali, MPH, Doneal Thomas, M.Phil, M.Sc, Kelly L. Davison, MD PhD, Sarit Assouline, MD, Luca Petruccelli, Chantal Cassis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4775.
https://doi.org/10.1182/blood-2019-129428
Published: 2019
Journal Articles

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the United States

Free
François Laliberté, Monika Raut, Xiaoqin Yang, Guillaume Germain, MSc, Shuvayu S Sen, Sean D. MacKnight, Kaushal D Desai, Mei Sheng Duh
Journal: Blood
Blood (2019) 134 (Supplement_1): 4720.
https://doi.org/10.1182/blood-2019-128876
Published: 2019
Journal Articles

PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma

Free
Jeong A Park, MD PhD, Hong fen Guo, PhD, Hong Xu, PhD, Nai-Kong V. Cheung, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1959.
https://doi.org/10.1182/blood-2019-131325
Published: 2019
Journal Articles

Biomarker Assessment of Venous Thromboembolism in Cancer Patients Receiving Checkpoint Blockade

Free
Shadi Swaidani, MD PhD, Joanna Roopkumar, MBBS, MPH, Young Jun-Shim, PhD, Cathy Charles, Slato Paul, Suman Kundu, MBA, Pauline Funchain, MD, Patricia Rayman, Paul G. Pavicic, C. Marcela Diaz-Montero, PhD, Alok A Khorana, MD, Keith R McCrae, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3648.
https://doi.org/10.1182/blood-2019-130911
Published: 2019